Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care
Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason庐 genomics program.
The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.
This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.
Fresenius Medical Care (NYSE:FMS) ha annunciato una collaborazione strategica tra la sua organizzazione di ricerca Frenova, Nephronomics e GENEWIZ di Azenta Life Sciences per avanzare nell'analisi genomica delle malattie renali attraverso il programma genomico My Reason庐.
La collaborazione sfrutta il registro di oltre 35.000 partecipanti di Frenova (con l'obiettivo di raggiungere 50.000 in due anni) per creare il pi霉 grande database mondiale di malattie cardio-renali-metaboliche. GENEWIZ fornir脿 il sequenziamento del DNA e la conservazione dei campioni biologici, mentre Nephronomics detiene i diritti commerciali esclusivi per sviluppare terapie mirate utilizzando modelli di intelligenza artificiale e machine learning.
Questa iniziativa mira a trasformare la cura renale attraverso la medicina personalizzata, analizzando i meccanismi genetici alla base delle malattie renali, cardiovascolari e metaboliche.
Fresenius Medical Care (NYSE:FMS) anunci贸 una colaboraci贸n estrat茅gica entre su organizaci贸n de investigaci贸n Frenova, Nephronomics y GENEWIZ de Azenta Life Sciences para avanzar en el an谩lisis gen贸mico de enfermedades renales a trav茅s del programa gen贸mico My Reason庐.
La colaboraci贸n aprovecha el registro de m谩s de 35,000 participantes de Frenova (con la meta de alcanzar 50,000 en dos a帽os) para crear la base de datos m谩s grande del mundo sobre enfermedades cardio-renales-metab贸licas. GENEWIZ proporcionar谩 secuenciaci贸n de ADN y almacenamiento de muestras biol贸gicas, mientras que Nephronomics posee los derechos comerciales exclusivos para desarrollar terapias dirigidas usando modelos de IA/ML.
Esta iniciativa busca transformar el cuidado renal mediante la medicina personalizada, analizando los mecanismos gen茅ticos subyacentes a las enfermedades renales, cardiovasculares y metab贸licas.
Fresenius Medical Care (NYSE:FMS)電� 鞛愳偓鞚� 鞐瓣惮 旮瓣磤鞚� Frenova, Nephronomics, 攴鸽Μ瓿� Azenta Life Sciences鞚� GENEWIZ鞕� 鞝勲灥鞝� 順戨牓鞚� 氚滍憸頃橃棳 My Reason庐 鞙犾爠觳� 頂勲攴鸽灗鞚� 韱淀暣 鞁犾灔 歆堩櫂鞚� 鞙犾爠觳� 攵勳劃鞚� 歆勳爠鞁滍偆瓿犾瀽 頃╇媹雼�.
鞚措矆 順戨牓鞚� Frenova鞚� 35,000氇� 鞚挫儊鞚� 彀戈皜鞛� 霌彪攵�(2雲� 雮� 50,000氇� 氇╉憸)毳� 頇滌毄頃橃棳 靹戈硠 斓滊寑鞚� 鞁灔-鞁犾灔-雽�靷� 歆堩櫂 雿办澊韯半矤鞚挫姢毳� 甑稌頃╇媹雼�. GENEWIZ電� DNA 鞁滍��鞁标臣 靸濎泊 鞁滊 氤搓磤鞚� 鞝滉车頃橂┌, Nephronomics電� AI/ML 氇嵏鞚� 頇滌毄頃� 響滌爜 旃橂 臧滊皽鞐� 雽�頃� 霃呾爯 靸侅梾 甓岆Μ毳� 氤挫湢頃╇媹雼�.
鞚� 鞚措媹靺旐嫲敫岆姅 鞁犾灔, 鞁槇甏� 氚� 雽�靷� 歆堩櫂鞚� 鞙犾爠鞝� 氅旍护雼堨鞚� 攵勳劃頃橃棳 臧滌澑 毵烄钉 鞚橅暀鞚� 韱淀暣 鞁犾灔 旃橂毳� 順侅嫚頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Fresenius Medical Care (NYSE:FMS) a annonc茅 une collaboration strat茅gique entre son organisation de recherche Frenova, Nephronomics et GENEWIZ d'Azenta Life Sciences pour faire progresser l'analyse g茅nomique des maladies r茅nales via le programme g茅nomique My Reason庐.
Cette collaboration s'appuie sur le registre de plus de 35 000 participants de Frenova (objectif de 50 000 en deux ans) pour cr茅er la plus grande base de donn茅es mondiale sur les maladies cardio-r茅nales-m茅taboliques. GENEWIZ fournira le s茅quen莽age de l'ADN et la conservation des 茅chantillons biologiques, tandis que Nephronomics d茅tient les droits commerciaux exclusifs pour d茅velopper des th茅rapies cibl茅es utilisant des mod猫les d'IA/ML.
Cette initiative vise 脿 transformer les soins r茅naux gr芒ce 脿 la m茅decine personnalis茅e en analysant les m茅canismes g茅n茅tiques sous-jacents aux maladies r茅nales, cardiovasculaires et m茅taboliques.
Fresenius Medical Care (NYSE:FMS) k眉ndigte eine strategische Zusammenarbeit zwischen seiner Forschungseinrichtung Frenova, Nephronomics und GENEWIZ von Azenta Life Sciences an, um die genomische Analyse von Nierenerkrankungen durch das My Reason庐 Genomik-Programm voranzutreiben.
Die Zusammenarbeit nutzt Frenovas Register mit 眉ber 35.000 Teilnehmern (Ziel: 50.000 in zwei Jahren), um die weltweit gr枚脽te Datenbank f眉r Herz-Kreislauf-Nieren-Metabolikerkrankungen zu schaffen. GENEWIZ wird DNA-Sequenzierung und Lagerung von Biospezimen bereitstellen, w盲hrend Nephronomics die exklusiven kommerziellen Rechte zur Entwicklung gezielter Therapien mit KI/ML-Modellen besitzt.
Diese Initiative zielt darauf ab, die Nierenversorgung durch personalisierte Medizin zu revolutionieren, indem die genetischen Mechanismen von Nieren-, Herz-Kreislauf- und Stoffwechselerkrankungen analysiert werden.
- Creation of world's largest kidney disease genomic database with over 35,000 participants
- Strategic partnership with leading genomics companies enhances research capabilities
- Potential for development of personalized treatments and improved patient outcomes
- Exclusive commercial rights secured through Nephronomics for therapy development
- Significant investment required for large-scale genomic sequencing and analysis
- Long development timeline before potential therapeutic applications
- Complex regulatory pathway for precision medicine approvals
Insights
Fresenius expands precision medicine capabilities through genomic collaboration, potentially transforming kidney disease treatment with personalized approaches.
This strategic collaboration between Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences represents a significant advancement in precision medicine for kidney disease. The partnership leverages Frenova's My Reason庐 genomics program, which has already collected biospecimens from over 35,000 participants with a goal of reaching 50,000 in the next two years.
The collaboration's scientific value lies in creating what could become the world's largest genotype-phenotype database specifically for patients with cardiovascular, kidney, and metabolic diseases. GENEWIZ will apply validated DNA sequencing technologies to generate large-scale genomic data from the collected biospecimens, while also providing long-term sample storage through Azenta's global biorepository network.
What makes this database particularly valuable is its focus on end-stage kidney disease patients, where genetic signals are often strongest and most detectable. Nephronomics holds exclusive commercial rights to this dataset (called the Nephronomics Atlas) and plans to apply proprietary AI/machine learning models to identify novel disease subtypes, protective genetic variants, and potential therapeutic targets.
The scientific implications are substantial: by correlating genetic information with detailed clinical data from Fresenius's extensive patient network, researchers can potentially identify specific genetic markers that influence disease progression, treatment response, and outcomes. This approach could eventually lead to more targeted interventions based on individual genetic profiles rather than the current more generalized approaches to kidney disease management.
From a business perspective, this collaboration strategically positions Fresenius Medical Care to expand beyond its traditional role as a dialysis provider into the high-growth precision medicine market. The partnership effectively combines Fresenius's extensive clinical footprint with cutting-edge genomic capabilities from GENEWIZ/Azenta and Nephronomics's specialized focus on renal precision medicine.
The business model is particularly interesting - Fresenius has effectively created a valuable data asset through Frenova's patient registry, then co-founded Nephronomics (a joint venture with Mechanica Partners) which now holds exclusive commercial rights to monetize this dataset. This structure allows Fresenius to participate in the upside of precision medicine innovations while sharing investment risk.
For context, precision medicine represents one of healthcare's fastest-growing segments, with the global precision medicine market projected to reach
The collaboration creates multiple potential revenue streams: licensing the dataset to pharmaceutical companies for drug discovery, developing proprietary diagnostics to identify patient subtypes, and eventually creating targeted therapies based on genetic insights. While financial terms weren't disclosed, similar genomic databases have generated significant licensing revenues.
Additionally, this initiative strengthens Fresenius's competitive positioning against other dialysis providers by establishing leadership in the emerging precision nephrology field. As reimbursement models increasingly shift toward value-based care, the ability to precisely stratify patients and personalize treatment approaches creates meaningful differentiation in the marketplace.
- Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences
- Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason庐 genomic and clinical data registry
- Paves way for advances in precision kidney disease care, novel therapies, and diagnostics
BAD HOMBURG,
Genomics-driven medicine, also known as听personalized medicine听or听precision medicine, uses an individual's genetic information, specifically their genome, to guide medical decisions.听This approach uses genomic analysis to understand a patient's unique biological makeup, enabling more targeted and effective treatments, diagnostics, and preventative strategies.
"Kidney disease affects each individual differently, shaped by their unique biology and genetic makeup," said Frank Maddux, M.D., Global Chief Medical Officer and member of the Management Board at Fresenius Medical Care AG. "These differences influence not only how the disease manifests, but also which treatments and therapies are most effective. By harnessing advanced genetic and molecular insights, we can transform kidney care鈥攎aking it more personalized, precise, and responsive to each patient's distinct needs. This collaboration paves the way for innovative diagnostics and therapies, enabling truly individualized clinical interventions and redefining what it means to be patient centric."
Frenova's My Reason庐 genomics research program is a kidney-focused data registry composed of genomic and clinical patient data designed to uncover insights into the genetic mechanisms underlying kidney disease. To date, more than 35,000 participants have been registered in the program and provided biospecimens, with a goal of reaching 50,000 participants over the next two years. The collaboration provides the analysis and gene sequencing necessary to extract the data's rich insights.
"This large-scale whole genome sequencing initiative marks a pivotal milestone in our journey to build the most comprehensive genotype-phenotype database for patients with cardiovascular, kidney, and metabolic diseases," said Jan Walter, President of Frenova. "We are excited to collaborate with Nephronomics on the interrogation of the Nephronomics Atlas to unlock unprecedented insights that could transform patient care."
"The My Reason庐 dataset, built through Frenova's unparalleled reach and expertise in nephrology care, represents the world's most robust end-stage kidney disease cohort, where many genetic signals are strongest," said James Sietstra, Founder of Nephronomics. "This collaboration will enable us to unlock new insights that not only advance scientific understanding but also translate into genetically informed therapeutics in the cardio-kidney-metabolic field."
"We are thrilled to partner with Frenova and Nephronomics and contribute to the My Reason庐 research program," said Ginger Zhou, President, GENEWIZ. "This collaboration represents a significant step forward in our shared mission to advance precision medicine and improve outcomes for patients."
Nephronomics holds exclusive commercial rights to the My Reason庐 dataset, which anchors the Nephronomics Atlas, a resource of deep clinical and genomic cardio-kidney-metabolic (CKM) disease data. Nephronomics aims to develop targeted therapies and redefine CKM disease care through precision medicine insights. By leveraging proprietary artificial intelligence (AI)/machine learning (ML) models trained on this comprehensive dataset, Nephronomics identifies novel disease subtypes, protective genetic variants, and therapeutic targets.
As part of this collaboration, GENEWIZ will apply its validated DNA sequencing technologies and expertise, to generate large-scale genomic data from biospecimens collected through Frenova's extensive nephrology research network. In addition to sequencing, Azenta will also provide long-term storage of samples through its global biorepository network. With over 25 years of experience in DNA sequencing and multiomics analysis, Azenta is uniquely positioned to provide end-to-end solutions for complex research programs.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at听.
About Frenova:
Frenova is a Fresenius Medical Care company that operates as a global Site Management Organization (SMO) dedicated听to the management and execution of third-party clinical trials focusing on Cardio-Kidney-Metabolic (CKM) related therapeutic areas. Leveraging our relationship听with Fresenius Medical Care's global dialysis clinics and partner nephrology practices, Frenova provides access to a global site network, streamlined procedures, and technology-enabled subject screening and enrollment. Frenova also offers data analytics and licensing services, with access to one of the nephrology听industry's largest longitudinal听patient听databases.
For more information visit the company's website at .
About Nephronomics:
Nephronomics, a joint venture between Mechanica Partners and Fresenius Medical Care, isassembling the world's largest vertically integrated cardio-kidney-metabolic (CKM) disease database and deep learning model with >35,000 patients consented. The Nephronomics Atlas contains matching whole genome and longitudinal clinical data of patients with advanced CKD and ESKD including comprehensive laboratory data, diagnosis histories, treatments, and raw radiology images.
For more information, please visit .
About Azenta Life Sciences:
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in
For more information, please visit .
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Kirsten Stratton
T +1 781 929 8096
[email protected]听
Christine Peters
T +49 160 60 66 770
[email protected]听
Contact for analysts and听investors
Dr. Dominik Heger
T +49 6172 609 2601
[email protected]听
View original content to download multimedia:
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What is the goal of Fresenius Medical Care's My Reason庐 genomics program?
Who are the key partners in FMS's new genomic research collaboration?
What is Nephronomics' role in the FMS genomics collaboration?
How will this genomics collaboration benefit kidney disease patients?
What is the current scale of Fresenius Medical Care's operations?
